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Many studies support the role of ultraviolet B in sun-
light-induced alteration of the cutaneous immune
system. The role of ultraviolet A is less clear, par-
ticularly in humans. The aim of this study was to
determine the effect of additional ultraviolet A on
solar-simulated ultraviolet-induced suppression of
recall responses to nickel in humans. Immuno-
suppression dose±responses were induced in volun-
teers by exposure to solar-simulated ultraviolet
radiation for four consecutive days. The ultraviolet A
radiation dose was increased daily by providing addi-
tional high-dose ultraviolet A either before, or after
the solar-simulated ultraviolet radiation. These ultra-
violet A doses can be readily achieved through a sun-
screen. Two different ultraviolet A spectra were
used; 320±400 nm and 330±400 nm. Ultraviolet A
alone did not cause signi®cant immunosuppression,
but augmented solar-simulated ultraviolet radiation-
induced immunosuppression. Additional ultraviolet
A reduced the minimum dose of solar-simulated
ultraviolet radiation that was immunosuppressive.
Both ultraviolet A spectra had this effect, although
photoaugmentation was less pronounced with the
330±400 nm spectrum. Ultraviolet A-induced
immediate pigment darkening did not protect from
solar-simulated ultraviolet radiation-induced immuno-
suppression. Key words: sunlight/nickel/erythema index/
immediate pigment darkening. J Invest Dermatol 118:1032±
1037, 2002
U
ltraviolet (UV) radiation has been identi®ed as a
cause of both immune suppression and skin cancer
(Everett et al, 1966; Yoshikawa et al, 1990; Giles
et al, 1996). Kinlen et al (1979) noted that patients
receiving long-term immunosuppressive therapy
had a high incidence of cutaneous malignancy. A better under-
standing of the complex biologic interactions of UV wavelength,
dose, and timing of exposure is required, so that more effective
interventions and therapies may be developed for the prevention of
skin cancer.
Of the UV wavelengths emitted by the sun, both UVB and
UVA reach the earth's surface. These wavelengths are de®ned as:
UVB (290±320 nm), UVAII (320±340 nm), and UVAI (340±
400 nm). The cutaneous effects of UV radiation result from the
penetration and absorption of particular wavelengths. UVB is
known to cause two biologic events that culminate in skin cancer:
(i) direct genetic damage, including the formation of pyrimidine
dimers and 6±4 photoproducts (Mitchell, 1988; Kraemer, 1997),
and (ii) immunosuppression (Kripke et al, 1992). In addition, UVB
induces delayed erythema, melanin pigmentation, and solar elastosis
(Gilchrest et al, 1996). Although the photobiologic effectiveness of
wavelengths longer than 320 nm is decreased, the sun emits higher
intensities of radiation in this range and this varies with the time of
day and the region (Peak et al, 1987; de Gruijl et al, 1993). Humans
receive a relatively high dose of UVA at dawn, dusk, during winter,
and through the use of sunscreens, tanning beds, and phototherapy.
UVA causes genetic damage and can contribute to skin cancer
(Runger, 1999). UVA has been estimated to contribute 10±20% to
the carcinogenic dose of sunlight (de Laat et al, 1997).
It is well recognized that UVB interferes with cell-mediated
immunity to contact allergens applied to the site of irradiation
(Yoshikawa et al, 1990), but the effect of UVA is less well de®ned.
Whether UVA augments, inhibits, or does not alter immuno-
suppression is a controversial issue, with con¯icting data existing in
the literature. These diverse results may be due to different
irradiation protocols, differences between animals and humans, or
to the different types of immune end-points studied. LeVee et al
(1997), found that after a single, local exposure of four minimal
erythemal doses (MED) of UVAII, using a xenon-arc lamp ®ltered
with a narrow band-pass ®lter (335 6 5 nm), signi®cantly fewer
volunteers were contact sensitized to dinitrochlorobenzene than in
the control group. Using a similar primary contact hypersensitivity
(CHS) model in humans, UVA (340±400 nm) offered partial
protection from UVB-induced immune suppression to diphenyl-
cyclopropenone (Skov et al, 2000). Other groups have been unable
to demonstrate any detectable suppression or protection of the
immune system after UVA radiation in humans (Sjovall and
Christensen, 1986; Skov et al, 1997). In mice, UVA has been
shown to be immunosuppressive (Bestak and Halliday, 1996) and
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to augment the incidence of UVB-induced tumors (Staberg et al,
1983; Strickland, 1986). In contrast to these ®ndings, Reeve et al
(1998) demonstrated that high doses of UVA from a ¯uorescent
lamp source, ®ltered through window glass to remove the shorter
UVA wavelengths, protected hairless mice from UVB-induced
immunosuppression. This protection was shown to involve the
induction of interferon-g and heme oxygenase (Reeve and Tyrrell,
1999). Thus, the part UVA plays in immune modulation requires
clari®cation.
The biologic role for immediate pigment darkening (IPD)
remains poorly understood. IPD is a transitory darkening of the
skin observed within seconds after UVA exposure, which subse-
quently decreases rapidly (Szabo et al, 1969). It involves structural
changes in melanocytes and keratinocytes and a chemical modi-
®cation of pre-existing melanin (Lavker and Kaidbey, 1982). On
the other hand, delayed tanning is caused by an increased melanin
density localized to the basal layer or increased synthesis and transfer
of melanized melanosomes to the epidermis (Jimbow et al, 1973).
The role of IPD in immune modulation and sunburn protection is
still unknown.
To study the effects of increased UVA exposure, and IPD, on
modulation of the skin immune system caused by sunlight, a model
previously developed by our group for studying solar-simulated UV
radiation (ssUVR) suppression of the challenge phase to a recall
antigen was utilized (Damian et al, 1997, 1999).
MATERIALS AND METHODS
Subjects Volunteers were recruited from the University of Sydney
(students and staff), general population, and staff from the Royal Prince
Alfred Hospital (Sydney, NSW, Australia). Exclusion criteria included
any sun exposure to the lower back 6 wk prior to entry into the study,
less than 18 y of age, photosensitivity or relative immunosuppression
through medications or illness, history of chronic disease, lactation or
pregnancy, and abnormal skin at the test site. All volunteers provided
written informed consent prior to entry into the study. Subjects were
recruited with approval from both the Central Sydney Area Health
Services and the University of Sydney Ethics Committees.
Eighty-seven (six males, 81 females) healthy, nickel-allergic volunteers,
of Fitzpatrick skin types I±IV (Fitzpatrick, 1988) were recruited. In
addition, 30 age-matched and skin-type-matched volunteers were used
for determination of minimum erythemal doses (®ve males, 25 females).
The average age of the volunteers was 38.0 6 1.4 y and the average
MED was 4.1 6 0.2 J per cm2 of ssUVR. All nickel-allergic subjects
commencing the study, completed it. Nine subjects were excluded from
the results due to insuf®cient CHS reactions (lack of con¯uent
induration) at both the UV-irradiated and non-UV-irradiated sites,
despite adequate reactions at the initial test sites.
Nickel patch testing To determine the degree of nickel sensitivity in
each volunteer, the left side of the lower back was initially patch tested
with nickel sulfate (NiSO4.6H2O) in a petrolatum base. Three
concentrations of nickel sulfate (Trolab, Germany), from 0.0125 to 5%,
with an additional petrolatum-only control, were applied to the left
lateral back in 9 mm Finn chambers (Epitest, Tuusula, Finland) (Fischer
and Rystedt, 1985; Fisher et al, 1989). The patches remained in situ for
48 h, with the reactions assessed 24 h after patch removal, using both a
clinical scoring system and a re¯ectance spectrometer (Diastron,
Hampshire, U.K.). The erythema index (EI) was calculated as the
difference between the average of four erythema readings at each of the
test sites and adjacent skin using the re¯ectance spectrometer. Clinically,
each reaction was graded from 1 to 10 depending on the degree of
vesiculation and induration. The lowest nickel concentration resulting in
a uniform, erythematous reaction with papules was determined for each
subject. This concentration was then used for the main study.
UV source A 1000 W ozone-free xenon arc lamp with a collimated
7.5 cm square beam (Oriel, Stratford, CT) was used as the ssUVR
source. The lamp emission was ®ltered by two 280±400 nm dichroic
mirrors, which attenuated the visible and infrared components of the
light source. To provide ssUVR, an ``atmospheric attenuation ®lter''
(Oriel catalog number 81017) with a spectral cut-off of 290±400 nm,
was used to modify the output spectrum. A 320±400 nm UVA spectrum
(referred to as 320±400 nm UVA) was generated using a ``UVB/C
blocking ®lter'' (Oriel catalog number 81050) in addition to the two
dichroic mirrors. Additional ®ltering through window glass was used, as
described by Reeve et al (1998), to attenuate the shorter UVA
wavelengths and produce a 330±400 nm UVA spectrum.
The solar-simulated and UVA spectra were monitored at 2 nm
intervals using a calibrated OL-65 A spectroradiometer (Optronic
Laboratories, Orlando, FL) (Fig 1). The proportions of UV radiation
that were contained in the simulated UV sources are shown in Table I.
Spectral irradiance was determined at least daily with an IL1350
broadband radiometer using SED 038 (UVA) and SED 240 (UVB)
detectors (International Light, Newburyport, MA) calibrated against the
xenon-arc solar simulator (Commonwealth Scienti®c and Industrial
Research Organization, Sydney, Australia). The integrated irradiance of
the solar-simulated UV at the skin surface measured at 7.5 cm was
5.1 mW per cm2 UVB (290±320 nm), 11.8 mW per cm2 UVAII (320±
340 nm), and 39.2 mW per cm2 UVAI (340±400 nm). The 320±400 nm
UVA had an irradiance of 5.1 mW per cm2 UVB, 4.1 mW per cm2
Figure 1. Comparison of the ssUVR and
UVA radiation spectra with sunlight. The solar
UV spectral irradiance is the noon solar spectrum
on a cloudless October day, in Sydney, Australia,
2001. The spectra used in this study, ssUVR, 320±
400 nm UVA and 330±400 nm UVA were
measured in 2 nm intervals using a calibrated
spectroradiometer (Optronic Laboratories Inc.,
Orlando, FL). All spectra are normalized to 1.0 at
360 nm.
Table I. Relative proportions of UV wavebands in each
studied spectrum
1000 W Oriel Solar
simulator
spectrum
% of UVR in each spectral region
UVB
(290±320 nm)
UVAII
(320±340 nm)
UVAI
(340±400 nm)
ssUVR (290±320 nm) 9.1 21.0 69.9
UVA (320±400 nm) 0.01 9.5 90.4
UVA (330±400 nm) 0.0002a 2.7b 97.3
a76.1% of the UVB found in this spectrum was > 315 nm.
b93.9% of the UVAII in this spectrum was found between 330 and 340 nm.
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UVAII, and 39.1 mW per cm2 UVAI. The longer wavelength 330±
400 nm UVA had an irradiance of 0.06 mW per cm2 UVB, 0.6 mW per
cm2 UVAII, and 21.4 mW per cm2 UVAI.
Determination of UVA and ssUVR-induced immunosuppression
Protocol for UV irradiation For the immunosuppression studies, volunteers
were irradiated within two separate 6 3 6 cm areas, on each side of the
lower back. Each area was subdivided into six, 2 3 3 cm regions. One
side of the back was randomly allocated to ssUVR with additional UVA
and the other to ssUVR only.
Each volunteer received four ®xed doses of ssUVR on separate
regions. Some regions received additional UVA, with control patches
receiving either no radiation, or UVA only (Fig 2). The suberythemal
doses of ssUVR given to each volunteer were; 0.6, 1, 1.5, and 2 J per
cm2 ssUVR, equivalent to 0.14, 0.24, 0.37, and 0.49 of an average
MED. The same protocol was administered daily, for four consecutive
days. This protocol has been previously demonstrated by our group to
induce immunosuppression in human volunteers (Damian et al, 1997).
There were three study groups. Sixteen volunteers received 17.8 J per
cm2 320±400 nm UVA after the ssUVR daily doses, and 30 volunteers
received this UVA prior to the ssUVR. A further group of 16 subjects
received 17.8 J per cm2 330±400 nm UVA after the ssUVR. The UVA
radiation given to subjects was equivalent to the amount found in 3 h of
midday summer sun in Australia, and therefore is a biologically achiev-
able dose.
Determination of immunosuppression On the fourth and ®nal day of
irradiation, a nickel patch was applied to each of the eight test sites and
to the two sites receiving no ssUVR or UVA, and two sites receiving
UVA alone. The patches were left in situ for 48 h. Nickel-induced
erythema and induration was assessed 21±28 h after patch removal, both
clinically and with the re¯ectance spectrometer described above. The
re¯ectance spectrometer measures re¯ected light at different wavelengths,
enabling the determination of both an IE and MI. The EI quantitates the
nickel-induced erythema, whereas the MI quantitates pigmentation.
Effect of UVA on the MED
MED The MED was determined on the lower back, for each
volunteer. A series of ten 6 3 6 mm squares were irradiated with
increasing, equal increments of ssUVR. The MED was de®ned as the
lowest dose of ssUVR at which clearly demarcated erythema was
visualized at 24 h postirradiation. To determine if UVA (320±400 nm)
had any effect on ssUVR-induced erythema, an additional 17.8 J per
cm2 UVA was delivered either before or after the ssUVR in two groups
of 15 volunteers.
Measurement of IPD Immediately prior to, then after irradiation of
subjects with UVA alone, four background readings of MI and EI were
taken with the re¯ectance spectrometer and averaged. These readings
were obtained to determine both the increase in pigmentation (MI) as a
measure of IPD and any immediate and delayed erythemal effect (EI).
Analysis of data The IE was calculated as the difference between the
average of four nickel-induced erythema readings at the test site
compared with adjacent skin. Immunosuppression was calculated as:
immunosuppression (DEI) = EI (unirradiated control) ± EI (test site)
Statistical comparisons were made by comparing CHS responses at the
unirradiated (control) sites, with the test sites via paired two-tailed
Student's t tests. Results are presented as the mean 6 SEM and are
considered signi®cant if p < 0.05.
RESULTS
Suberythemal ssUVR irradiation did not impair the nickel
CHS response at distant sites Initial trial patches were applied
on to non-UV-irradiated sites on subject's lateral mid-backs, prior
to UV irradiation of adjacent sites. Clinical scoring of these
reactions demonstrated that they were, on average, the same or
smaller than the responses that subsequently occurred at the non-
UV-irradiated control sites. Hence our UV irradiation protocol did
not suppress the CHS reaction at adjacent nonirradiated sites.
SsUVR-induced immunosuppression is augmented by
additional 320±400 nm UVA Augmentation of ssUVR-
induced immunosuppression occurred in response to all doses of
ssUVR that received additional 320±400 nm UVA. Additional
17.8 J per cm2 of 320±400 nm UVA given after ssUVR,
augmented the level of immunosuppression at each ssUVR dose
(Fig 3a). With the addition of UVA, a statistically signi®cant level
of immunosuppression occurred at a dose of 1.5 J per cm2 ssUVR.
The test sites that received ssUVR alone, without additional UVA,
also demonstrated immunosuppression in a dose-related manner;
however, only the highest dose of ssUVR tested (2 J per cm2)
caused a level of immunosuppression that reached statistical
signi®cance. The small degree of immunosuppression resulting
from the 320±400 nm UVA alone was not statistically signi®cant.
A similar result occurred when the 320±400 nm UVA was given
before the ssUVR (Fig 3b). ssUVR alone resulted in a dose-related
immunosuppression; however, as in the previous experiment, only
the highest dose of ssUVR (2 J per cm2) caused a signi®cant level of
immunosuppression. Irradiation with an additional ®xed dose of
17.8 J per cm2 of 320±400 nm UVA prior to ssUVR, approxim-
ately doubled the level of immunosuppression resulting from
ssUVR given in the absence of UVA. Again, with the additional
UVA, statistically signi®cant immunosuppression occurred at a
lower ssUVR dose (1.5 J per cm2). The UVA alone did not cause
any detectable immunosuppression in this experiment.
Thus, supplementation of ssUVR with additional 320±400 nm
UVA applied either before, or after the ssUVR increased the level
Figure 2. Schematic representation of the
test site on each subject's lower back. Two
6 cm squares on each side of the lower back were
divided into six regions each. Four different doses
of ssUVR were given to each side, with one side
randomly allocated to receive an additional 17.8 J
per cm2 UVA. This irradiation protocol was given
to the same test sites daily, for four consecutive
days.
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of immunosuppression, decreasing the minimum dose of ssUVR
required to cause signi®cant levels of immunosuppression.
The 17.8 J per cm2 320±400 nm UVA dose that augments
immunosuppression also caused IPD The 17.8 J per cm2 of
320±400 nm UVA used in the above experiments resulted in a
clinically observable increase in pigmentation, occurring within
seconds after UV exposure. This is termed IPD. The ssUVR
(which was at much lower doses) did not have this effect. To
quantitate this pigmentation, the MI was measured by a re¯ectance
spectrometer. A single dose of 17.8 J per cm2 320±400 nm UVA
caused a signi®cant increase in the MI by a mean of 11.7 6 4.4
(16%) from the background reading (paired Student's t test;
p < 0.02). This increase in MI was equivalent to the difference in
MI readings between Fitzpatrick I and II skin types at unexposed
sites. A nonsigni®cant, transient increase in erythema of 13% was
observed immediately post-UVA irradiation, which faded within
minutes. As it faded too rapidly to be sunburn, it was probably
increased blood ¯ow caused by heat generated during the
irradiation. As this UVA regimen augmented immunosuppression
(Fig 3) whether it was applied before or after ssUVR (i.e., ssUVR
irradiation in the presence or absence of IPD), IPD did not protect
from immunosuppression.
The 17.8 J per cm2 320±400 nm UVA augments erythema
To determine whether the additional 17.8 J per cm2 320±400 nm
UVA affected ssUVR-induced erythema, two groups of 15 non-
nickel-allergic volunteers were recruited. Subjects were irradiated
with incremental doses of ssUVR, with or without additional UVA
(Table II). Additional UVA given either before or after ssUVR
augmented ssUVR-induced erythema by causing a similar,
signi®cant decrease in the MED. Thus, the ability of the skin to
burn was not protected by IPD, as similar results were observed
whether the ssUVR was given to skin in which IPD had or had not
been induced.
SsUVR-induced immunosuppression is augmented by
additional 330±400 nm UVA In a separate experiment, the
320±400 nm UVA spectrum was additionally ®ltered with window
glass to remove the majority of the wavelengths between 320 and
330 nm (Fig 1). These subjects received the same 17.8 J per cm2 of
additional UVA given after the ssUVR, but with a different
spectrum (Fig 4). In this experiment the 330±400 nm UVA alone
did not cause immunosuppression. In the absence of additional
UVA, ssUVR caused immunosuppression in a dose-related manner
and, like the previous experiments, only the highest dose of ssUVR
alone (2 J per cm2) resulted in a level of immunosuppression that
reached statistical signi®cance. Supplementation of each ssUVR
dose with 17.8 J per cm2 of 330±400 nm UVA increased the level
of immunosuppression by 27% (average increase in immuno-
suppression over the four ssUVR doses tested). This is much less
than the doubling of immunosuppression that resulted from the
additional 320±400 nm UVA (Fig 3). Supplementation of ssUVR
with the 330±400 nm UVA reduced the minimum dose of ssUVR
that caused signi®cant immunosuppression from 2 to 1.5 J per cm2.
Thus, 330±400 nm UVA augments ssUVR-induced immuno-
suppression, but not to the same extent as 320±400 nm UVA.
DISCUSSION
Studies have previously developed a nickel model in humans to
investigate UV-radiation-induced suppression of CHS (Damian
et al, 1997, 1999). In these experiments, there is UV-induced
suppression of the effector, CHS response to a recall antigen. This
protocol enables the determination of UV-immunosuppressive
dose±responses in a single group of volunteers. In these experi-
ments it was demonstrated that two different UVA spectra (320±
400 nm and 330±400 nm) augmented the immune suppression
induced by ssUVR; 320±400 nm had a greater effect than 330±
400 nm, indicating that wavelengths in the 320±330 nm band were
important for mediating the suppressive effect of UVA radiation. It
is well recognized that UVAII has similar properties to UVB,
Figure 3. ssUVR-induced immunosuppression is augmented by
additional 320±400 nm UVA. A group of 16 volunteers were exposed
daily to a range of doses of ssUVR (0, 0.6, 1, 1.5, or 2 J per cm2). Some
skin areas received an additional 17.8 J per cm2 UVA (320±400 nm).
UVA was given either after (a)or before (b)ssUVR. Each skin region
received an identical exposure for each of four consecutive days,
followed by nickel patch testing. The area with no ssUVR received
UVA only and the area which received neither ssUVR nor UVA was
the positive, unirradiated control to which all other sites were compared.
Nickel-induced erythema was measured by re¯ectance spectroscopy and
is shown as EI. Mean 6 SEM are shown. Paired two-tailed Student's t
test. *Signi®cance; p < 0.05, compared with unirradiated control site.
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whereas the biologic effects of UVAI appear to be distinct from
UVB (Mutzhas et al, 1991). We also show for the ®rst time that
IPD induced by high-dose UVA does not protect from ssUVR-
induced immune suppression.
In previous studies by our group, nickel-induced erythema
measured by re¯ectance spectroscopy was demonstrated to parallel
the clinical intensity of the nickel patch test reactions. The
erythema indices and clinical scores increased linearly against the
log of the nickel concentrations. In addition, UV did not
signi®cantly suppress the erythema resulting from application of
sodium lauryl sulfate, a nonspeci®c irritant (Damian et al, 1997).
Hence, it was con®rmed that this model measures immunosup-
pression, rather than nonspeci®c reduction in in¯ammation.
In mice, the UVA component of both 5 and 10 MED of ssUVR
has been demonstrated to protect against UVB-induced suppression
(Reeve et al, 1998). We sought to determine whether a similar dose
and spectrum of UVA as used by Reeve et al (1998) modulated UV
suppression of recall responses in humans. A relatively high dose of
UVA was used in these studies, equivalent to about 3 h in the
midday summer sun. Relatively high doses of UVA may
commonly be received by sunlight ®ltered through window glass,
or sunscreens. Tanning lamps also deliver high UVA irradiances.
Therefore, humans can be readily exposed to the UVA doses used
in this study.
UVA-induced immunoprotection was not observed in this
study. These experiments differed from those of Reeve et al (1998),
who studied suppression of the induction of systemic immuno-
suppression in mice, in comparison with the challenge phase of the
CHS response in humans used in these studies. Our contrasting
results may re¯ect differences between humans and mice, or the
different types of immune responses studied. We went to great
lengths to mimic the dose and UVA spectra of UVA used by Reeve
et al (1998) so this is unlikely to account for the different results
observed. In our study, the minimum dose of ssUVR that induced
immunosuppression was four daily doses of 2 J per cm2. In contrast,
signi®cant immunosuppression occurred at 1.5 J per cm2 ssUVR
when additional UVA was given either before or after ssUVR.
Both UVA spectra lowered the minimum dose of ssUVR that
caused signi®cant immunosuppression, but the 320±400 nm UVA
spectrum had a larger effect than the 330±400 nm spectrum. This
suggests that 320±330 nm UVA, as well as wavelengths above
330 nm can at least contribute to immunosuppression.
The time course, UV spectrum, and dose are each important
factors for immunomodulation. Using the same model as in this
study, our group has previously demonstrated that a 3 d irradiation
protocol of 2 J per cm2 320±400 nm UVA on consecutive days
caused immunosuppression. This immunosuppression was not
evident with longer irradiation protocols (Damian et al, 1999).
No immunosuppression occurred in our current study using a
considerably higher dose of 320±400 nm UVA (17.8 J per cm2)
given alone, over four consecutive days. Thus these studies show
that 4 d of UVA alone does not cause immunosuppression. These
results are also consistent with those of Sjovall and Christensen
(1986) and Skov et al (1997), who did not observe immuno-
suppression in response to UVA radiation alone, in humans. Skov et
al (1997) assessed the induction of CHS to diphenylcycloprope-
none, following exposure to a single dose of 3 MED UVA.
Several previous human studies support our observations that
UVA contributes to immunosuppression. Using the same nickel
recall model, immunosuppression has been demonstrated to be
greater after UV irradiation of human skin protected with a narrow
spectrum sunscreen compared with a broad-spectrum sunscreen.
Addition of sunscreen agents that attenuate UVA such as zinc
oxide, were required to prevent signi®cant immunosuppression
(Damian et al, 1999). Other studies have con®rmed that sunscreens
with UVA protection provide better inhibition of immunosup-
pression than UVB-only protective sunscreens (Fourtanier et al,
2000). High-dose, chronic ssUVR and UVA delivered to large
surface areas of the body have also been shown to cause local and
systemic suppression of delayed-type hypersensitivity responses to
recall antigens in humans (Moyal et al, 1997).
Table II. Comparison of the MED obtained after incremental doses of ssUVR, with or without additional UVA, in two
separate trials
Trial
MEDc (J per cm2)
ssUVR
MED (J per cm2)
UVAd before ssUVR
MED (J per cm2)
UVAd after ssUVR pe n
1a 3.8 6 0.3 3.0 6 0.3 < 0.04 15
2b 6.0 6 0.9 5.3 6 0.8 < 0.002 15
aFitzpatrick skin types: 11 type II, 3 type III, 1 type IV.
bFitzpatrick skin types: 2 type I, 5 type II, 5 type III, 1 type IV, 2 type V.
cThe MED is the minimum dose of ssUVR at which clearly demarcated erythema was visualized at 24 h post irradiation.
dThe additional UVA was a ®xed dose of 17.8 J per cm2 320±400 nm UVA.
eStudent's two-tailed paired t test.
Figure 4. ssUVR-induced immunosuppression is augmented by
additional 330±400 nm UVA. A group of 16 volunteers were exposed
daily to a range of doses of ssUVR (0, 0.6, 1, 1.5, or 2 J per cm2) on
different regions of skin. Some skin areas received an additional 17.8 J
per cm2 UVA (330±400 nm) after the ssUVR. Each skin region received
an identical exposure for each of four consecutive days, followed by
nickel patch testing. The area with no ssUVR received UVA only and
the area that received neither ssUVR nor UVA was the positive,
unirradiated control to which all other sites were compared. Nickel-
induced erythema was measured by re¯ectance spectroscopy and is
shown as EI. Mean 6 SEM are shown. Paired two-tailed Student's t
test. *Signi®cance; p < 0.05, compared with unirradiated control site.
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The biologic role of UVA-induced IPD remains poorly
understood. Very little work has been performed on IPD in the
past decade and no previous studies have examined its effect on the
human cutaneous immune system. UVA (320±400 nm) given prior
to ssUVR-induced IPD prior to subjects receiving ssUVR. In
contrast, as IPD fades rapidly in Fitzpatrick skin types I and II,
subjects given UVA after ssUVR received the ssUVR in the
absence of IPD. There was no difference between the above
groups, demonstrating that IPD did not inhibit immunosuppression
(Fig 3). Thus, the chemical and structural changes that occur with
IPD do not protect the human skin immune system from ssUVR.
Similarly, consistent with previous studies (Paul and Parrish, 1982;
Black et al, 1985), IPD did not affect the MED, showing that it also
did not protect from sunburn.
To determine any effect of additional UVA on the MED, we
gave the ®xed dose of UVA either before or after incremental doses
of ssUVR. Additional UVA signi®cantly reduced the amount of
ssUVR required to induce an MED. This photoaddition, or
augmentation of UVB-induced erythema by UVA, has been
demonstrated in previous studies (Paul and Parrish, 1982; Willis et al
1973; Ying et al, 1974; Spiegel et al, 1978). Thus, the results of this
study were not unexpected, as we show that UVA contributes to
erythema in addition to photoaugmentation of immunosuppres-
sion.
Thus we have demonstrated that high-dose UVA exacerbates
ssUVR-induced suppression of the elicitation of contact sensitivity
in humans. The additional UVA lowered the minimum dose of
ssUVR required to cause signi®cant immunosuppression. Both
320±400 nm and 330±400 nm UVA were effective, although the
spectrum that included the 320±330 nm waveband had a larger
effect. UVA-induced IPD did not provide any protection to the
immune system. UVA is undoubtedly immunomodulatory, but its
effects are likely to be dependent on the dose, wavelength, timing,
and immune parameter being assessed. Complex interactions
between different wavelengths are likely to occur. We cannot
exclude the probability that UVA could have the opposite effect to
the one we have observed under different circumstances.
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was supported by an Australian Postgraduate Award.
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